Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

NCT02254044 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Squamous Cell

Interventions

DRUG: bivatuzumab mertansine

Sponsor

Boehringer Ingelheim